Amtagvi (lifileucel)
ATMP
- Region
- 🇪🇺 EU
- Active substance
- lifileucel
- Company
- Iovance Biotherapeutics B.V.
- Status
- Application withdrawn
- Therapeutic area
- Melanoma
- Designations
- ATMP
- Application
- EMEA/H/C/004741
- ATC
- L01XL11
- Official record
- www.ema.europa.eu
Indication
Treatment of unresectable or metastatic melanoma
Regulatory milestones
No milestones recorded in the last year.
Follow Amtagvi
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.